Ph1/2 study of Rova-T in combination with nivolumab (Nivo) +/- ipilimumab (Ipi) for patients (pts) with 2L+extensive-stage (ED) SCLC.

Malhotra, J; Nikolinakos, P; Leal, T; Lehman, J; Morgensztern, D; Patel, JD; Wrangle, JM; Curigliano, G; Dansin, E; Greillier, L; Johnson, ML; Ready, N; Robinet, G; Lally, S; Wong, S; Avsar, E; Valenzuela, R; Scripture, CD; Selvaggi, G; Besse, B

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索